Clinical efficacy of Liuwei Anshen capsule combined with Escitalopram in the treatment of depression
Objective To investigate the clinical efficacy of Liuwei Anshen capsule combined with Escitalopram in the treatment of depression.Methods A totoal of 150 patients with depression who were treated in 904th Joint Logistics Support Force Hospital Chan-gzhou Medical Area from January 2022 to January 2024 were selected as the study objects.Patients were divided into group A(n=72)and group B(n=78)according to different treatment regiments.Group A was treated with escitalopram,group B was treated with Li-uwei Anshen capsule combined with Escitalopram.The clinical efficacy and incidence of adverse reactions were recorded and compared between the two groups.The score of short form 36 questionnaire(SF-36),beck scale for suicide ideation(BSS),neurotransmitter[nor-epinephrine(NE),5-hydroxy tryptamine(5-HT),dopamine dopamine(DA)],inflammatory factors[interleukin(IL)-6,IL-22,IL-1β]before and after treatment were compared between the two groups.And the expression level of toll-like receptor 4/NOD-like receptor 3(TLR4/NLRP3)pathway.Results The total effective rate of group B was 89.74%(70/78),which was higher than 59.72%(43/72)of group A,and the difference was statistically significant(P＜0.05).After treatment,SF-36 score increased and BSS score decreased in both groups,and SF-36 score in group B was higher than that in group A,and BSS score was lower than that in group A,with statisti-cal significance(P＜0.05).After treatment,IL-6,IL-21 and IL-1β in 2 groups were decreased,while NE,5-HT and DA were in-creased,and IL-6,IL-21 and IL-1β in group B were lower than those in group A,while NE,5-HT and DA were higher than those in group A,with statistical significance(P＜0.05).After treatment,TLR4 mRNA and NLRP3 mRNA were decreased in 2 groups,and group B was lower than group A,the differences were statistically significant(P＜0.05).The incidence of adverse reactions in group A and group B was 2.78%(2/72)and 3.85%(3/78),respectively,with no statistical significance(P＞0.05).Conclusion Liuwei Anshen capsule combined with Escitalopram is effective in the treatment of depression,and can improve symptoms,levels of inflamma-tory factors and neurotransmitters.The down-regulation of pro-inflammatory factors such as IL-6,IL-21 and IL-1β may be related to the inhibition of TLR4/NLRP3 pathway expression.
万方数据
维普
